Abstract:Psoriasis is a systemic, immune-mediated disorder, characterized by inflammatory skin and joint manifestations. A range of co-morbidities is associated with psoriasis, including metabolic diseases, such as diabetes, and psychological disorders. Although the systemic nature of psoriasis often remains unrecognized, the inflammatory processes involved may be associated with the development of co-morbidities, which, themselves, have a significant impact on the patient's health and quality of life. The relative risks of myocardial infarction (MI) and stroke are increased in patients with psoriasis compared with the general population. These are especially seen in younger patients with more severe disease, and are believed to contribute to the 3- to 4-year reduction in life expectancy among patients with severe psoriasis. The recent results of large studies indicate that the increased cardiovascular (CV) risk is at least partially attributable to psoriasis and independent of the presence of metabolic co-morbidities. The possible interplay between psoriasis and CV disease is complex. Metabolic diseases such as obesity and diabetes have overlapping genetic predispositions with psoriasis. Both conditions are likely to also interact at a functional level because obesity and the up-regulation of pro-inflammatory mediators in psoriasis appear to influence adipocyte homoeostasis, inducing non-professional immune functions. This may perpetuate psoriatic inflammation, displaying similarities to the immunopathogenesis of atherosclerosis. Finally, the disturbed adipokine profile and inflammation associated with psoriasis enhances insulin resistance, causing subsequent endothelial dysfunction, atherosclerosis and eventual coronary events. The differential contribution of psoriasis and uncontrolled classical CV risk factors to the increased CV risk seen in psoriasis patients is not clear. Successful treatment with methotrexate appears to lower the rates of MI in patients with psoriasis. Tumour necrosis factor-α (TNF-α) inhibitors are known to counteract insulin resistance and emerging studies demonstrate an even higher protective effect of TNF-α antagonist therapy against the development of diabetes or CV co-morbidities in patients. The recent data reviewed here indicate a role for earlier and more appropriate treatment of psoriasis with drugs such as TNF-α antagonists. Such an approach has the potential to significantly improve patient outcomes through the treatment of psoriasis itself and possibly also in protection against co-morbidities.

Autoimmune Skin Conditions: Psoriasis

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review

Psoriasis. Definition and Classification of A Complex Entity

Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and treatment

Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated

Types of Psoriasis and Their Effects on the Immune System

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review

The cardiometabolic conditions of psoriatic disease

The concept of psoriasis as a systemic inflammation: implications for disease management

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

The Psychosocial Burden Of Psoriasis: Understanding The Impact On Mental Health And Well-Being

Association between the systemic treatment of psoriasis and cardiovascular risk

Pathogenesis, Multi-Omics Research, and Clinical Treatment of Psoriasis.

Psoriasis and its association with metabolic syndrome

Current Concepts of Psoriasis Immunopathogenesis

Cardiovascular comorbidity in psoriasis – psoriatic inflammation is more than just skin deep

Pathophysiology of psoriasis: A review

Risk Factors for the Development of Psoriasis

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis

Psoriasis management tree based on comorbidity